nach oben

Annals of Nuclear Medicine

Erschienen in:

01.12.2009 | Original Article

Donepezil- and scopolamine-induced rCMRglu changes assessed by PET in conscious rhesus monkeys

verfasst von: Makoto Asai, Akihiko Fujikawa, Akihiro Noda, Sosuke Miyoshi, Nobuya Matsuoka, Shintaro Nishimura

Erschienen in: Annals of Nuclear Medicine | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

[¹⁸F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) is a useful tool for measuring the regional cerebral metabolic rate of glucose (rCMRglu), which is an index of neuronal activity. Donepezil, an acetylcholine esterase inhibitor (AChEI), has been recommended as a treatment option for patients with Alzheimer’s disease (AD). We aimed to characterize the effects of donepezil on rCMRglu using FDG-PET in non-human primates.

Methods

We investigated the effects of administration of donepezil (500 μg/kg, i.m.), the non-selective muscarinic ACh receptor antagonist scopolamine (30 μg/kg, i.m.), and the coadministration of both drugs on the rCMRglu of conscious young rhesus monkeys.

Results

Donepezil increased the rCMRglu in all regions of interest except in the thalamus. Scopolamine treatment also increased the rCMRglu in all regions of interest except the cerebellum and thalamus. However, these effects disappeared with coadministration of the drugs.

Conclusions

This PET study showed that administration of donepezil or scopolamine alone increased the rCMRglu in conscious rhesus monkeys. We also found that the donepezil-induced increase was abolished by simultaneous administration of scopolamine, suggesting that muscarinic ACh receptor function plays an important role in the effect of donepezil.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30(8):1104–13.CrossRefPubMed

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46(10):1625–32.PubMed

Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21(7):453–78.CrossRefPubMed

Modrego PJ. The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques. Curr Med Chem. 2006;13(28):3417–24.CrossRefPubMed

Teipel SJ, Drzezga A, Bartenstein P, Moller HJ, Schwaiger M, Hampel H. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer’s disease: a double-blind cross-over trial. Psychopharmacology (Berl). 2006;187(1):86–94.CrossRef

Stefanova E, Wall A, Almkvist O, Nilsson A, Forsberg A, Langstrom B, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease. J Neural Transm. 2006;113(2):205–18.CrossRefPubMed

Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol. 2005;62(5):721–8.CrossRefPubMed

De-Mello N, Souza-Junior IQ, Carobrez AP. Pilocarpine prevents age-related spatial learning impairments in rats. Behav Brain Res. 2005;158(2):263–8.CrossRefPubMed

Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML, et al. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Ther. 2006;316(2):679–94.CrossRefPubMed

10.

Prediger RD, De-Mello N, Takahashi RN. Pilocarpine improves olfactory discrimination and social recognition memory deficits in 24 month-old rats. Eur J Pharmacol. 2006;531(1–3):176–82.CrossRefPubMed

11.

Green A, Ellis KA, Ellis J, Bartholomeusz CF, Ilic S, Croft RJ, et al. Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol Biochem Behav. 2005;81(3):575–84.CrossRefPubMed

12.

Buccafusco JJ, Terry AV Jr, Decker MW, Gopalakrishnan M. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol. 2007;74(8):1202–11.CrossRefPubMed

13.

Onoe H, Inoue O, Suzuki K, Tsukada H, Itoh T, Mataga N, et al. Ketamine increases the striatal N-[11C]methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey. Brain Res. 1994;663(2):191–8.CrossRefPubMed

14.

Rupniak NM, Tye SJ, Field MJ. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology (Berl). 1997;131(4):406–10.CrossRef

15.

Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T, et al. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci. 1997;44:1277–82.CrossRef

16.

Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28(5):897–916.CrossRefPubMed

17.

Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-d-glucose: validation of method. Ann Neurol. 1979;6(5):371–88.CrossRefPubMed

18.

Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, et al. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab. 1985;5(2):179–92.PubMed

19.

Cross DJ, Minoshima S, Nishimura S, Noda A, Tsukada H, Kuhl DE. Three-dimensional stereotactic surface projection analysis of macaque brain PET: development and initial applications. J Nucl Med. 2000;41(11):1879–87.PubMed

20.

Blin J, Ray CA, Piercey MF, Bartko JJ, Mouradian MM, Chase TN. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography. Brain Res. 1994;635(1–2):196–202.CrossRefPubMed

21.

Mishima K, Iwasaki K, Tsukikawa H, Matsumoto Y, Egashira N, Abe K, et al. The scopolamine-induced impairment of spatial cognition parallels the acetylcholine release in the ventral hippocampus in rats. Jpn J Pharmacol. 2000;84(2):163–73.CrossRefPubMed

22.

Vannucchi MG, Scali C, Kopf SR, Pepeu G, Casamenti F. Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience. 1997;79(3):837–46.CrossRefPubMed

23.

Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19(1):58–67.CrossRefPubMed

24.

Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging. 2008;29(8):1204–17.CrossRefPubMed

25.

Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000;48(3):391–5.CrossRefPubMed

Titel: Donepezil- and scopolamine-induced rCMRglu changes assessed by PET in conscious rhesus monkeys
verfasst von: Makoto Asai
Akihiko Fujikawa
Akihiro Noda
Sosuke Miyoshi
Nobuya Matsuoka
Shintaro Nishimura
Publikationsdatum: 01.12.2009
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 10/2009
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-009-0316-7

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2009

Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site

Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT

Bibliometric study of radiation application on microdose useful for new drug development

The relationship between reverse redistribution of 99mTc-tetrofosmin in sub-acute phase and left ventricular functional recovery in chronic phase in patients with acute myocardial infarction

Impact of additional SPECT in bone scanning in tumor patients with suspected metastatic bone disease

Prognostic value of myocardial perfusion SPECT images in combination with the maximal heart rate at exercise testing in Japanese patients with suspected ischemic heart disease: a sub-analysis of J-ACCESS